





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|---|
| (51) International Patent Classification ⁷ : C07C 227/04, 229/28, 205/51 | | A1 | (11) International Publication Number: WO 00/39074 |
| | | | (43) International Publication Date: 6 July 2000 (06.07.00) |
| (21) International Application Number: PCT/HU99/00102 (22) International Filing Date: 23 December 1999 (23.12.99) (30) Priority Data: P 9803034 29 December 1998 (29.12.98) HU (71) Applicant (for all designated States except US): RICHTER GEDEON VEGYÉSZETI GYÁR RT. [HU/HU]; Gyömrői út 19-21, H-1103 Budapest X. (HU). (72) Inventors; and (75) Inventors/Applicants (for US only): GIZUR, Tibor [HU/HU]; Avarszállás u. 30, H-1162 Budapest (HU), LENGYEL, Zoltánné [HU/HU]; Zirzen J. u. 40/c., H-1125 Budapest (HU). SZALAI, Krisztina [HU/HU]; Sarkadi út 2. VI. em. 20., H-1039 Budapest (HU). (74) Common Representative: RICHTER GEDEON VEGYÉSZETI GYÁR RT.; Gyömrői út 19-21, H-1103 Budapest X. (HU). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. | |
| (54) Title: PROCESS FOR THE SYNTHESIS OF 1-(AMINOMETHYL)CYCLOHEXYL-ACETIC ACID | | | |
| <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(II)</p> </div> </div> | | | |
| (57) Abstract <p>The invention relates to a new process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid of formula (I) via the new intermediate 1-(nitromethyl)cyclohexyl-acetic acid derivative of formula (II), wherein R represents hydrogen, benzyl group, diphenylmethyl group or C₁-C₄ alkyl or alkoxy aromatic ring substituted derivatives thereof.</p> | | | |

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

BEST AVAILABLE COPY

Process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid

The invention relates to a new process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid of the formula (I) via the new
5 intermediate 1-(nitromethyl)cyclohexyl-acetic acid derivative of general formula (II), wherein R represents hydrogen, benzyl group, diphenylmethyl group or C₁-C₄ alkyl or alkoxy aromatic ring substituted derivatives thereof.



The 1-(aminomethyl)cyclohexyl-acetic acid of formula (I), otherwise known as gabapentin is the active ingredient of the GABA antagonist drug. Several methods are known from the literature for the synthesis of
15 this compound.

In most of the known methods an intermediate is hydrolysed with acid, and gabapentin is obtained from the so formed gabapentin hydrochloride salt by using ion exchange resin. This process is described in the German patent No. DE 2 460 891, in which the 1,1-cyclohexyldiacetic acid anhydride is converted into hydroxamic acid and
20 the latter is transformed via Lossen degradation into the hydrochloride salt of the product. The US patent No. US 4 024 175 describes a method where the same 1,1-cyclohexyldiacetic acid anhydride is used as starting material. The anhydride is first transformed into a monomethyl ester
25 monosalt and then a monoacid monoazide is obtained from it. The gabapentin hydrochloride is prepared from the latter via Curtius degradation.

Similarly gabapentin hydrochloride is formed in the procedure described in the European patent No. EP 414 274. According to this

invention the alkyl ester of 1-(nitromethyl)acetic acid is transformed into a 2-aza-spiro[4,5]decane-3-on derivative by catalytic hydrogenation. The gabapentin hydrochloride is obtained from the latter lactam derivative by refluxing it with hydrochloric acid and gabapentin is isolated by using ion-exchange resin.


The disadvantages of the above mentioned procedures are as follows. The gabapentin is obtained as its hydrochloride salt and gabapentin itself can be isolated only by using labour-demanding and expensive ion-exchange method. To avoid the unwanted lactam formation side-reaction requires also a labour-demanding and expensive technique. Further disadvantages of these procedures are the use of hazardous reagents, e.g. potassium cyanide, sodium azide and the expensive pressure resistant equipment.

The procedure described in the European patent No. EP 414 275 avoids the formation of the lactam compound and the gabapentin hydrochloride, and this way the use of the expensive ion-exchange method. According to this procedure cyano-cyclohexane-maleinic acid derivatives are hydrolysed with base, decarboxylated and finally the nitril group is catalytically hydrogenated. On the other hand this patent does not describe the synthesis of the cyano-cyclohexane-maleinic acid derivatives, which is a multi step, tedious process. It is important to note, that the synthesis of the maleinic acid ester is four steps starting from cyclohexanon, so the synthesis of gabapentin is altogether seven steps. The patent does not mention the purity of the obtained gabapentin either, in contrast to other patents, which describe the synthesis of gabapentin, e.g. EP 414 274.

The aim the invention is to elaborate an economical, industrially applicable process for the synthesis of gabapentin, which eliminates the disadvantages of the above mentioned procedures and makes possible the simple synthesis of the very pure final product of formula (I) in fewer steps and in good yield.

The synthesis of gabapentin according to the process of the invention is as follows

- a) the alkyl ester of cyclohexylidene-acetic acid of general formula (VI) — wherein R_2 represents C_1 - C_4 alkyl group — is transformed into the alkyl ester of 1-(nitromethyl)cyclohexyl-acetic acid of general formula (V) —
5 wherein the meaning of R_2 is as defined above — with nitromethane in the presence of a base, the latter is hydrolysed with aqueous methanolic solution of potassium hydroxide and the obtained 1-(nitromethyl)cyclohexyl-acetic acid of formula (IIa) is hydrogenated in a
10 solvent in the presence of a catalyst to yield the desired product of formula (I), or




15

- b) the alkyl ester of cyclohexylidene-acetic acid of general formula (VI) — wherein the meaning of R_2 is as defined above — is hydrolysed with aqueous methanolic solution of potassium hydroxide and the obtained
20 cyclohexylidene-acetic acid of formula (IV) is reacted with a reagent of formula R_1 -X — wherein R_1 represents benzyl group, diphenylmethyl group or in given case C_1 - C_4 alkyl or alkoxy aromatic ring substituted derivatives thereof — to give the appropriate cyclohexylidene acid derivative of general formula (III) — wherein the meaning of R_1 is as
25 defined above — and this intermediar is transformed into 1-(nitromethyl)cyclohexyl-acetic acid derivative of general formula (IIb) —

wherein the meaning of R_1 is as defined above — with nitromethane and the latter is hydrogenated in a solvent in the presence of a catalyst.



5



The process of the invention is illustrated on Scheme 1.

The invention based on the observation, that the reduction of the new compounds of general formula (II) at atmospheric pressure yields directly the pure desired final product.

Surprisingly it was found, that using the compounds of general formula (II) as starting materials in the reduction step the lactam compound is not formed, but the very pure gabapentin is obtained directly. This was not anticipated in the knowledge of previous procedures, as the ability of lactam formation of this type of compounds is known from the literature (e.g. EP 414 274).

The alkyl ester of cyclohexylideneacetic acid of general formula (VI) used as starting material can be prepared according to the literature via the reaction of cyclohexanone and the appropriate ester of diethylphosphono-acetic acid.

In the last hydrogenation step any catalysts can be used, which are generally applicable in hydrogenation reactions, rare metal catalysts, e.g. rhodium or palladium, Raney nickel or cobalt catalysts, in given case on a carrier e.g. on carbon, preferably palladium on activated carbon, more preferably 10% of the compound to be reduced.

The hydrogenation is carried out in an inert organic solvent, preferably in a C_1 - C_4 alcohol, more preferably in methanol, at 10-50°C,

under 1-20 kPa pressure, preferably at room temperature and under atmospheric pressure.

The Michael addition of the ester of cyclohexylidene-acetic acid with nitromethane is carried out in the presence of a base, preferably
5 potassium hydroxide.

The hydrolysis of the alkyl ester group is carried out with base, preferably aqueous methanolic solution of potassium hydroxide at room temperature, then the acid is liberated with 10% aqueous potassium dihydrogenphosphate solution.

10 After filtration of the catalyst the product is isolated by concentration of the filtrate. The product obtained on concentration is 98-99% pure, the yield is 50-70%.

The advantages of this procedure are as follows:

- the obtained product is very pure
- 15 — the number of reaction steps is less than in the known procedures
- the lactam compound, which is very difficult to remove, is not formed
- neither special pressure resistant equipment nor expensive catalyst is needed
- the final product can be obtained without applying difficult and
20 complicated ion-exchange technology
- no poisonous or dangerous materials are needed

Examples

Example 1

25 a) Synthesis of 1-(nitromethyl)cyclohexyl-acetic acid

A solution of 4.3 g (0.02 mol) of methyl 1-(nitromethyl)cyclohexyl-acetate in a mixture of 50 ml of methanol and 20 ml of 10% aqueous potassium hydroxide is stirred at room temperature for 24 h, then the methanol is distilled off in vacuo. The pH of the resulted aqueous solution is adjusted
30 to 7 with 10% aqueous potassium dihydrogenphosphate solution. The

solution is extracted three times with 30 ml of ethyl acetate, the combined organic layers are dried over sodium sulphate and concentrated to yield 3.2 g (80%) of the title compound as oil.

5 b) Synthesis of 1-(aminomethyl)cyclohexyl-acetic acid

A solution of 2.01 g (0.01 mol) of 1-(nitromethyl)cyclohexyl-acetic acid in 50 ml of methanol is hydrogenated in the presence of 0.2 g of palladium on activated carbon at atmospheric pressure. The catalyst is filtered off and the filtrate is concentrated to 10 ml. 20 ml of tetrahydrofuran is added
10 to the residue and the precipitated crystals were filtered off and dried to yield 1.3 g (80%) of the title compound. Mp: 164-169°C

Example 2


Synthesis of 1-(aminomethyl)cyclohexyl-acetic acid

15 A solution of 5 g (0.017 mol) of benzyl 1-(nitromethyl)cyclohexyl-acetate in 50 ml of methanol is added to a mixture of 0.5 g of prehydrogenated palladium, 10% on activated carbon in 50 ml of methanol. This mixture is hydrogenated at room temperature under atmospheric pressure until the calculated hydrogen is consumed, then the catalyst is filtered off, the
20 filtrate is concentrated to about 15 ml and 30 ml of tetrahydrofuran is added to precipitate the title compound. Yield: 1.5 g (51%). Mp: 168°C.

Claims:


1. Process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid
5 acid and pharmaceutically acceptable salt thereof characterised by

a) transformation of the alkyl ester of cyclohexylidene-acetic acid of formula (VI) — wherein R_2 represents C_1 - C_4 alkyl group — into the alkyl ester of 1-(nitromethyl)cyclohexyl-acetic acid of formula (V) — wherein the meaning of R_2 is as defined above — with nitromethane in the presence of
10 a base, hydrolysis with aqueous methanolic solution of potassium hydroxide and hydrogenation of the obtained 1-(nitromethyl)cyclohexyl-acetic acid of formula (IIa) in the presence of a catalyst and in given case transformation of the obtained compound into a pharmaceutically acceptable salt or



b) hydrolysis of the alkyl ester of cyclohexylidene-acetic acid of formula (VI) — wherein R_2 represents C_1 - C_4 alkyl group — into the cyclohexylidene-acetic acid of formula (IV) with aqueous methanolic
20 solution of potassium hydroxide, reaction of the obtained acid of formula (IV) with a reagent of formula R_1 -X — wherein R_1 represents benzyl group, diphenylmethyl group or in given case C_1 - C_4 alkyl or alkoxy aromatic ring substituted derivatives thereof and X represents halogen atom — to give the intermediar cyclohexylidene acid derivative of formula (III) — wherein
25 the meaning of R_1 is as defined above — transformation of this intermediar into the 1-(nitromethyl)cyclohexyl-acetic acid derivative of formula (IIb) — wherein the meaning of R_1 is as defined above — and

hydrogenation of the latter in a solvent in the presence of a catalyst and in given case transformation of the obtained compound into a pharmaceutically acceptable salt.



5

2. Process b) of claim 1 characterised by using benzyl halide as reagent of formula R_1-X .

3. Process b) of claim 1 characterised by using diphenylmethyl halide as reagent of formula R_1-X .

10 4. The process of claim 1-3 characterised by carrying out the hydrogenation in an inert organic solvent.

5. The process of claim 1-3 characterised by using palladium on activated carbon as catalyst.

15 6. The new compounds of formula (II), wherein R represents hydrogen, benzyl, diphenylmethyl group or in given case C_1-C_4 alkyl or alkoxy aromatic ring substituted derivatives thereof.

7. 1-(nitromethyl)cyclohexyl-acetic acid

8. benzyl 1-(nitromethyl)cyclohexyl-acetate

9. diphenylmethyl 1-(nitromethyl)cyclohexyl-acetate

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/HU 99/00102

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C227/04 C07C229/28 C07C205/51

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | EP 0 414 274 A (GOEDECKE AG) 27 February 1991 (1991-02-27) cited in the application page 6 -page 12 --- | 1,4,5 |
| Y | BRYANS J S ET AL: "Investigation into the preferred conformation of Gabapentin for interaction with its binding site on the alpha2delta subunit of a calcium channel" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 19, 7 October 1997 (1997-10-07), pages 2481-2484, XP004136469 ISSN: 0960-894X the whole document --- -/-- | 1,4,5 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 March 2000

Date of mailing of the international search report

29/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/HU 99/00102

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A,P | WO 99 21824 A (BRYANS JUSTIN STEPHEN ;HORWELL DAVID CHRISTOPHER (GB); WARNER LAMB) 6 May 1999 (1999-05-06) page 27 -page 52; example 2 --- | 1-6 |
| A | EP 0 414 263 A (GOEDECKE AG) 27 February 1991 (1991-02-27) abstract --- | 1 |
| A | EP 0 432 504 A (LONZA AG) 19 June 1991 (1991-06-19) abstract; claim 1 --- | 1 |
| A | GARETH GRIFFITHS ET AL: "Novel Syntheses of Gabapentin via Addition of Hydrocyanic Acid to Cyclohexylidenemalonate or Cyano(cyclohexylidene)acetate" HELVETICA CHIMICA ACTA,CH,VERLAG HELVETICA CHIMICA ACTA. BASEL, vol. 74, no. 2, 1991, pages 309-314, XP002100736 ISSN: 0018-019X the whole document ----- | 1 |

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HU 99/00102

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|--|
| EP 0414274 A | 27-02-1991 | DE 3928182 A AT 90936 T DK 414274 T ES 2058707 T FI 103040 B HU 54623 A,B IL 95479 A JP 2846084 B JP 3118355 A US 5091567 A | 28-02-1991 15-07-1993 09-08-1993 01-11-1994 15-04-1999 28-03-1991 12-09-1996 13-01-1999 20-05-1991 25-02-1992 |
| WO 9921824 A | 06-05-1999 | AU 9663898 A | 17-05-1999 |
| EP 0414263 A | 27-02-1991 | DE 3928183 A AT 113272 T DE 59007550 D DK 414263 T ES 2063219 T HK 1003480 A IE 65291 B JP 3090053 A PT 95082 A,B | 28-02-1991 15-11-1994 01-12-1994 16-01-1995 01-01-1995 30-10-1998 18-10-1995 16-04-1991 18-04-1991 |
| EP 0432504 A | 19-06-1991 | AT 106861 T CA 2030107 A DE 59006037 D DK 432504 T ES 2057334 T FI 905584 A JP 3176459 A NO 177531 B PT 95894 A,B RU 2029761 C US 5095148 A US 5130455 A US 5149870 A US 5136091 A | 15-06-1994 17-05-1991 14-07-1994 04-07-1994 16-10-1994 17-05-1991 31-07-1991 26-06-1995 13-09-1991 27-02-1995 10-03-1992 14-07-1992 22-09-1992 04-08-1992 |

BEST AVAILABLE COPY